CURRICULUM VITAE

Name	Kamaljit Kaur
University Address	Chapman University School of Pharmacy (CUSP) Harry and Diane Rinker Health Science Campus 9401 Jeronimo Road, Suite 297-X Irvine, CA, 92618-1908 USA
	Tel: (714) 516-5494 Fax: (714) 516-5481
Email	kkaur@chapman.edu
Website	http://sites.chapman.edu/kaur/

I. ACADEMIC BACKGROUND

A. ACADEMIC APPOINTMENTS

06/2015-present:	Associate Professor (tenured), Chapman University School of Pharmacy (CUSP), Chapman University, Irvine, CA, USA
08/2016-02/2019:	Director, Center for Targeted Drug Delivery (CTDD), Chapman University, Irvine, CA, USA
08/2014-05/2015:	Distinguished Chancellor Fellow (0.2 FTE), Chapman University School of Pharmacy, Chapman University, Irvine, CA, USA
07/2012-05/2016:	Associate Professor (tenured), Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta, Canada (on leave 06/2015-05/2016)
04/2004-06/2012:	Assistant Professor, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Alberta, Canada
Delays	Maternity leave (05/2004-08/2004, 4 months) Childcare leave (09/2007-05/2008, 9 months)

B. EDUCATION AND TRAINING

2001-2004:	**Post-doctoral fellow** Department of Chemistry, University of Alberta, Alberta, Canada *Project:* Antimicrobial Peptides from Lactic Acid Bacteria (Supervisor: John C. Vederas)
1999-2001:	**Post-doctoral fellow**

Department of Chemistry, Wesleyan University, Connecticut, USA

Project: Design, Synthesis, and Evaluation of Acyl Phosph(on)ates as β-Lactamase Inhibitors (Supervisor: Rex F. Pratt)

1994-1998: **Ph.D.** in Bioorganic Chemistry
Department of Chemistry, Case Western Reserve University, Cleveland, Ohio, USA

Dissertation: Modification of Proteins by Oxidized Lipids in LDL and Human Plasma: Immunodetection and Prevention (Supervisor: Robert G. Salomon)

1995-1998: **Graduate Student Fellow**
Department of Cell Biology, Cleveland Clinic Foundation, Cleveland, Ohio, USA (Supervisor: Henry F. Hoff)

1993-1994: **Junior Research Fellow**
Department of Chemistry, Indian Institute of Technology, Kanpur, India (Supervisor: Yeshwant. D. Vankar)

1991-1993: **M.Sc.** in Organic Chemistry
Department of Chemistry, Indian Institute of Technology, Kanpur, India

Thesis Title: Synthesis of Some Useful Chiral Intermediates via Enzymatic Resolution (Supervisor: Yeshwant. D. Vankar)

1988-1991: **B.Sc. Honors** in Chemistry
Delhi University, New Delhi, India.

C. AWARDS AND AFFILIATIONS

2011	Thieme Chemistry Journals Award 2011
2005	New Opportunities Fund Award, Canada Foundation for Innovation
1998	Chemistry Department Fellowship, Depart. of Chemistry, CWRU, USA
1994	Graduate Aptitude Test in Engineering (GATE) Fellowship, India
1991-1993	Government Merit Scholarship for M.Sc., India
Since 1999	Member, American Chemical Society (ACS)
Since 2015	Member, American Association of Colleges of Pharmacy (AACP)
Since 2020	Member, American Association for Cancer Research (AACR)
2018-2019	Member, Materials Research Society (MRS)
2014-2016	Member, American Association of Pharmaceutical Scientists (AAPS)
2013-2016	Member, Canadian Federation of University Women (CFUW)
2005-2016	Member, Association of Faculties of Pharmacy of Canada (AFPC)
2000-2016	Member, Canadian Society for Chemistry (CSC)
2004-2015	Member, Canadian Society for Pharmaceutical Sciences (CSPS)

II. RESEARCH AND SCHOLARLY ACTIVITIES

A. RESEARCH INTERESTS

- Engineering Peptides and Peptide-mimetics for Biological Applications
- Peptide/Antibody Assisted Targeted Drug Delivery
- Cell-Surface Proteins
- Peptide-based Platforms for Developing Diagnostics for Cancer and Bacteria

RESEARCH EXPERTISE

Medicinal Chemistry; Targeted Drug Delivery; Breast Cancer; Pathogenic bacteria; Therapeutics; Diagnostics; Peptide Engineering; Antimicrobial Peptides

B. RESEARCH GRANTS

Source: Extramural Impact Award, Chapman University School of Pharmacy (California)
Title: Peptide-drug conjugates: A novel modality for triple-negative breast cancer treatment
(2022-2023)
Role: PI

Source: NIH-National Cancer Institute (NCI), Grant # 1R15CA208656-01A1
Title: Breast cancer targeting peptides for improved efficacy of current cancer treatment
(2017-2022)
Role: PI

Source: Chapman University School of Pharmacy (California) Start-Up Fund
Title: Targeted Drug Delivery and Biomedical Diagnostics
(2015-2019)
Role: PI

Source: Research Contract, Water Planet Inc., California, USA
Title: Method development for molecular weight determination of a polymer sample
(2016)
Role: PI

Source: Alberta Innovates Bio Solutions (Canada)
Title: Increasing the activity and yields of bacteriocins for use in the food and animal industries
Amount: $495,000 (May 2013-Apr 2016)
Role: PI (Co-PI: David Wishart and Lynn McMullen)

Source: Natural Sciences and Engineering Research Council of Canada (NSERC-Discovery)
Title: Investigation of Peptides and Peptidomimetics for Developing Bioactive Molecules
Amount: $125,000 (Apr 2011-Mar 2016)
Role: PI

Source: Saskatchewan Health Research Foundation (Canada)
Title: Development of Theranostic Agents for Melanoma

Amount: $100,000 (Mar 2015-Feb 2016)
Role: Co-PI (PI: Ildiko Badea)

Source: Canadian Institutes of Health Research (CIHR) Bridge Grant
Title: Nanodelivery Systems for Modulation of Chemotherapy Response in Invasive and Metastatic Breast Cancer
Amount: $100,000 (2014-2015)
Role: Co-PI (PI: Afsaneh Lavasanifar)

Source: Natural Sciences and Engineering Research Council of Canada (NSERC-Strategic Projects)
Title: Detection of Pathogenic Bacteria through Antimicrobial Peptide-based Cantilever Bio-MEMS (MicroElectroMechanical System) Sensor
Amount: $431,100 (2011-2014)
Role: PI (Co-PI: Thomas Thundat and Sushanta Mitra)

Source: Alberta Cancer Foundation Bridge Operating Grant (ACF-CIHR)
Title: Tumor targeted polymeric nanocarriers for oncogene silencing therapy of metastatic breast cancer
Amount: $100,000 (2013-2014)
Role: Co-PI (PI: Afsaneh Lavasanifar)

Source: Alberta Livestock and Meat Agency (ALMA)
Title: Novel bactericidal peptides against *Mannheimia hemolytica*-induced feedlot pneumonia in cattle
Amount: $90,532 (2011-2013)
Role: Co-PI (PI: Baljit Singh)

Source: Alberta Cancer Foundation Bridge Operating Grant (CIHR)
Title: Ligand guided polymeric nano-carriers for tumor targeted drug and oncogene silencing therapy
Amount: $100,000 (2011-2013)
Role: Co-PI (PI: Afsaneh Lavasanifar)

Source: International Project Fund (IPF) – University of Alberta
Title: Detection of Polynuclear Aromatic Hydrocarbons (PAHs) in Water Streams
Amount: $6,000 (2012)
Role: Co-PI (PI: Subir Bhattacharjee)

Source: JCR Biolab Inc. Irvine, CA, USA
Title: Development of a substrate-based reagent for the detection and enumeration of *E. coli*
Amount: $5,520 (2012)
Role: PI

Source: Canada Foundation for Innovation-Infrastructure Operating Fund (CFI-IOF)
Title: Biomolecular Design and Peptidomimetic Drug Discovery Laboratory
Amount: $41,036 (2007-2012)
Role: PI

Source: Canada Foundation for Innovation (CFI) and Alberta Advanced Education and Technology

Title: Facility to Support the Bench-to-bedside Development of Targeted Drugs and Drug Delivery Systems for Improved Therapeutic Performance
Amount: $906,271 (2011-2012)
Role: Co-PI (PI: Afsaneh Lavasanifar)

Source: Natural Sciences and Engineering Research Council of Canada (NSERC-Discovery)
Title: Peptidomimetic Approaches for Developing Biologically Active Molecules
Amount: $78,000 (2008-2011)
Role: PI

Source: NSERC-Research Tools and Instruments Grant (NSERC-RTI)
Title: Differential Scanning calorimetry for the development of new pharmaceuticals
Amount: $73,500 (2010-2011)
Role: Co-PI (PI: Afsaneh Lavasanifar)

Source: International Science and Technology Partnerships Canada Inc. (ISTP)
Title: Joint Indo-Canadian Meeting on Development of Low Cost Lab-on-a-Chip Medical Devices for Health Monitoring
Amount: $42,650 (2010-2011)
Role: Co-PI (PI: Thomas Thundat)

Source: NSERC-Collaborative Health Research Projects (NSERC-CHRP)
Title: A New Approach for Sensitization of Chemoresistant Cancers to Drug Therapy
Amount: $100,000 (2009-2010)
Role: Co-PI (PI: Hasan Uludag)

Source: Natural Sciences and Engineering Research Council of Canada (NSERC-Strategic Projects)
Title: Ligand guided polymeric nano-carriers for targeted vaccine and drug delivery in cancer
Amount: $649,707 (2006-2010)
Role: Co-PI (PI: John Samuel)

Source: Canada Foundation for Innovation (CFI)
Title: Biomolecular Design and Peptidomimetic Drug Discovery Laboratory
Amount: $342,031 (2005-2006)
Role: PI

Source: Department of Medicine Research Funds, University of Alberta
Title: Pilot Study for Allicin-mediated Decolonization of MRSA in Health Care Settings
Amount: $4,500 (2007-2008)
Role: Co-PI (PI: Kanna Alagiakrishnan)

Source: Canadian Institutes of Health Research (CIHR)
Title: Multi-user maintenance, equipment, and support for nuclear magnetic resonance (NMR) facility
Amount: $420,665 (2006-2010)
Role: Co-PI (PI: Edward Knaus)

Source: University of Alberta

Title: University of Alberta Start-Up Fund
(2004-2008)
Role: PI

C. RESEARCH COMMUNITY

Editorial Board Member

2020 – *Pharmaceutics* by MDPI
2017 – *Scientific Reports* by NPG

Conference Session Organizer

2025 ACS Spring 2025 Meeting and Exposition
Co-Organizer and Co-Chair, Session: *DNA-Encoded Libraries for Drug Discovery*
San Diego, California, Mar 23-27, 2025

2023 14th AFMC International Medicinal Chemistry Symposium 2023, Seoul, Korea
Organizer and Chair, Session: *Next-generation Peptide Therapeutics*
Seoul, Korea, June 25-28, 2023

2022 Gordon Research Conference (Chemistry & Biology of Peptides)
Co-Chair (Discussion Leader), Session: *Peptides in Oncology*
Oxnard, CA, USA, Oct 30-Nov 04, 2022

2019 American Peptide Symposium
Co-Chair, Session: *Peptides as Cellular Reagents*
Monterey, CA, USA, June 22-27, 2019

2015 PACIFICHEM 2015
Co-Chair, Session: *Cancer Targeted Delivery of Therapeutics and Diagnostics*
Honolulu, Hawaii, USA, Dec 15-20, 2015

2012 10th ASME 2012
Chair, Session: *Interfacial Phenomena at Micro and Nanoscale*
International Conference on Nanochannels, Microchannels and Minichannels
Rio Grande, Puerto Rico, July 8-12, 2012

2009 92nd Canadian Chemistry Conference and Exhibition
Chair, Session: *Peptides and Peptidomimetics*
Hamilton, ON, Canada, May 30-June 3, 2009

Grant Review Panel

2024 (Sep) *NCI Program Project P01 Review* (Special Emphasis)
2023-2025 Standing Committee Member, CIHR Project Grants, *Biomedical Engineering (BME)*
2022 (Jun) CIHR, *Biomedical Engineering 2 (BE2)*
2022 (Nov) NSF CAREER panel, Division of Molecular and Cellular Biosciences
2021 (Nov) *NCI Clinical & Transl. Exploratory/Developmental Studies* (Special Emphasis)
2021 (Mar) *NCI Clinical & Transl. Exploratory/Developmental Studies* (Special Emphasis)
2020 (Jul) *NIAID Emergency Awards: Rapid Investigation of SARS CoV-2 and COVID19*
2020 (Jun) *NCI Clinical & Transl. Exploratory/Developmental Studies* (Special Emphasis)
2020 (May) CIHR, *COVID-19 Rapid Research - Therapeutics*

2020 (Mar) *NCI Cancer Health Disparities* (Special Emphasis)
2020 (Feb) *NCI Clinical & Transl. Exploratory/Developmental Studies* (Special Emphasis)
2019 (Jun) *NCI Clinical & Transl. Exploratory/Developmental Studies* (Special Emphasis)
2018-present College of Reviewers Member, Canadian Institutes of Health Research (CIHR)
2016 (Jun) CIHR, *Stage 1 review process of the Project Grant competition*
2013 (Nov) CIHR, *Pharmaceutical Sciences Committee*
2011 (Apr) CIHR, *Pharmacology and Toxicology Committee*
2010–2015 Canadian Breast Cancer Foundation-Prairies/NWT Region

Reviewer for Grant Application

2023, Faculty Grant for Research, Scholarship, and Creative Activity, Chapman University
2022, Natural Sciences & Engineering Research Council of Canada (NSERC) Discovery Grant
2022, National Science Center Poland
2021, NSERC Discovery Grant
2019, Consortium for Medical Marijuana Clinical Outcomes Research
2019, CUNY University Research Grant Program
2018, IIT Bombay-Seed Grant Wadhwani Research Centre for Bioengineering
2018, Chapman University-Faculty Opportunity Fund
2016, New Investigator Award Application, AACP
2016, Ohio Cancer Research
2015, Saskatchewan Health Research Foundation, Establishment Grant Competition
2015, Cancer Care Manitoba Foundation
2014, University of Saskatchewan Establishment Grant Review
2014, One Health Research Development Grant Program
2013, French National Research Agency, ANR
2012, Multiple Sclerosis (MS) Society of Canada
2012, Manitoba Research Chairs, Manitoba Health Research Council
2010, British Columbia Innovation Council (BCIC) Innovation Scholars
2009-2013, NSERC Discovery Grants
2009, NSERC Collaborative Health Research Projects (CHRP)
2008, Research Corporation Grant, USA

Reviewer for Other Application(s)

2015, Promotion to Full Professor
2010 & 2011, GSK-AFPC Student Awards

Regular or Frequent Reviewer for following Journals

Analytical Chemistry; ACS Applied Materials and Interfaces; Biochimica et Biophysica Acta (BBA)-Biomembranes; BMC Microbiology; BMC Structural Biology; Bioconjugate Chemistry; Biomacromolecules; Bioorganic and Medicinal Chemistry; Bioorganic and Medicinal Chemistry Letters; Biopolymers; Chemical Biology & Drug Design; Chemical Reviews; ChemMedChem; Critical Reviews in Biotechnology; Drug Delivery and Translational Research; European Journal of Medicinal Chemistry; Environmental Science & Technology; Journal of Biomedicine and Biotechnology; Journal of the American Chemical Society (JACS); Journal of Cancer; Journal of

Chemical Information and Modeling; Journal of Combinatorial Chemistry; Journal of Medicinal Chemistry; Journal of Pharmacy & Pharmaceutical Sciences; Journal of Polymer Science, Part A: Polymer Chemistry; Langmuir; Molecular Pharmaceutics; Nature Communications; Organic Letters

D. RESEARCH CONTRIBUTIONS AND PRACTICAL APPLICATIONS

REFEREED JOURNAL PUBLICATIONS

Published (trainee names under my supervision are underlined, *corresponding author)
h index = 40 (total citations 4270) **Google Scholar; [n=76]**

1. Phi-Phung Than, Shih-Jing Yao, Emad Althagafi, **Kamaljit Kaur***, A Conjugate of an EGFR-Binding Peptide and Doxorubicin Shows Selective Toxicity to Triple-Negative Breast Cancer Cells, *ACS Med. Chem. Lett.*, **2025**, *16*, 109-115.
2. Devaraj V.Chandrashekar, G. Chuli Roules, Nataraj Jagadeesan, Urvashi R. Panchal, Adenike Oyegbesan, Oghenetega E. Imiruaye, Hai Zhang, Jerome Garcia, **Kamaljit Kaur**, Sanda Win, Tin A. Than, Neil Kaplowitz, Moom R. Roosan, Derick Han, Rachita K. Sumbria*, Hepatic LRP-1 plays an important role in amyloidosis in Alzheimer's disease mice: Potential role in chronic heavy alcohol feeding, *Neurobiol. Dis.*, **2024**, *199*, 106570.
3. Elmira Ziaei, Igor Moura de Paiva, Shih-Jing Yao, Nasim Sarrami, Parnian Mehinrad, Justine Lai, Afsaneh Lavasanifar*, **Kamaljit Kaur***, Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice, *Mol. Pharm.*, **2023**, *20*, 3570-3577.
4. Shirley Tong, Shaban Darwish, Hanieh Hossein Nejad Ariani, Kate Alison Lozada, David Salehi, Maris A. Cinelli, Richard B. Silverman, **Kamaljit Kaur***, Sun Yang*, A small peptide increases drug delivery in human melanoma cells, *Pharmaceutics* **2022**, *14*, 1036.
5. Oluseye Ogunnigbagbe, Christopher G. Bunick*, **Kamaljit Kaur***, Keratin 1 as a cell-surface receptor in cancer, Biochimica et Biophysica Acta (*BBA) – Reviews on Cancer* **2022**, *1877*, 188664.
6. Harpreet Dhingra, **Kamaljit Kaur**, Baljit Singh*, Engineering and characterization of human β-defensin-3 and its analogues and microcin J25 peptides against *Mannheimia haemolytica* and bovine neutrophils, *Vet. Res.* **2021**, *52*, 83.
7. Azam Saghaeidehkordi, Shiuan Chen, Sun Yang, **Kamaljit Kaur***, Evaluation of a keratin 1 targeting peptide-doxorubicin conjugate in a mouse model of triple-negative breast cancer, *Pharmaceutics* **2021**, *13*, 661.
8. Mona Alas, Azam Saghaeidehkordi, **Kamaljit Kaur***, Peptide-drug conjugates with different linkers for cancer therapy, J. Med. Chem. **2021**, *64*, 216-232.
9. E. Ziaei, A. Saghaeidehkordi, C. Dill, I. Maslennikov, S. Chen, **K. Kaur***, Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide-Doxorubicin Conjugates, *Biocon. Chem.*, **2019**, *30*, 3098-3106.
10. R. Soudy, R. Kimura, A. Patel, W. Fu, **K. Kaur**, D. Westaway, J. Yang, J. Jhamandas*, Short amylin receptor antagonist peptides improve memory deficits in Alzheimer's disease mouse model, *Sci. Rep. (Nature Publishing Group)*, **2019**, *9*, 10942:1-11.

11. H. Hossein-Nejad-Ariani, E. Althagafi, **K. Kaur***, Small peptide ligands for targeting EGFR in triple negative breast cancer cells, *Sci. Rep. (Nature Publishing Group)*, **2019**, *9*, 2723:1-10.
12. S.B. Patil, R.M. Al-Jehani, H. Etayash, V. Turbe, K. Jiang, J. Bailey, W. Al-Akkad, R. Soudy, **K. Kaur**, R.A. McKendry, T. Thundat, J.W. Ndieyira*, Modified cantilever arrays improve sensitivity and reproducibility of nanomechanical sensing in living cells, *Commun. Biol. (Nature Publishing Group)* **2018**, *1*, 175.
13. H. Soleymani Abyaneh, A.H. Soleimani, M.R. Vakili, R. Soudy, **K. Kaur**, F. Cuda, A. Tavassoli, A. Lavasanifar*, Modulation of Hypoxia-Induced Chemoresistance to Polymeric Micellar Cisplatin: The Effect of Ligand Modification of Micellar Carrier Versus Inhibition of the Mediators of Drug Resistance, *Pharmaceutics*, **2018**, *10*, 196.
14. W. Mohammed-Saeid, R. Soudy, R. Tikoo, **K. Kaur**, R. Verrall, I. Badea*, Design and evaluation of gemini surfactant-based lipoplexes modified with cell-binding peptide for targeted gene therapy in melanoma model, *J. Pharm. Pharm. Sci.*, **2018**, *21*, 363-375.
15. H. Hossein-Nejad-Ariani, T. Kim, **K. Kaur***, Peptide-based Biosensor Utilizing Fluorescent Gold Nanoclusters for Detection of *Listeria monocytogenes*, *ACS Appl. Nano Mater.,* **2018**, *1*, 3389-3397. (June 1, 2018)
16. W. Fu, V. Vukojevic, A. Patel, R. Soudy, D. MacTavish, D. Westaway, **K. Kaur**, V. Goncharuk, J. Jhamandas*, Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation, *J. Neuroinflammation*, **2017**, *14*, 199 (1-12). (Oct 6, 2017)
17. D.R. Balay, R.V. Dangeti, **K. Kaur**, L.M. McMullen*, Purification of leucocin A for use on wieners to inhibit Listeria monocytogenes in the presence of spoilage organisms, *Int. J. Food Microbiol.*, **2017**, *255*, 25-31. (Aug 16, 2017)
18. S.M. Garg, I.M. Paiva, M.R. Vakili, R. Soudy, K. Agopsowicz, A.H. Soleimani, M. Hitt, **K. Kaur**, A. Lavasanifar*, Traceable PEO-poly(ester) micelles for breast cancer targeting: The effect of core structure and targeting peptide on micellar tumor accumulation, *Biomaterials* **2017**, *144*, 17-29. (Aug 4, 2017)
19. Y. Raghuwanshi, H. Etayash, R. Soudy, I. Paiva, A. Lavasanifar, **K. Kaur***, Proteolytically stable cyclic decapeptide for breast cancer cell targeting, *J. Med. Chem.* **2017**, *60*, 4893-4903. (Jun 22, 2017)
20. R. Soudy, H. Etayash, K. Bahadorani, A. Lavasanifar, **K. Kaur***, Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer, *Mol. Pharm.*, **2017**, *14*, 593-604. (Mar 6, 2017)
21. R. Soudy, N. Byeon, Y. Raghuwanshi, S. Ahmed, A. Lavasanifar, **K. Kaur***, Engineered Peptides for Applications in Cancer Targeted Drug Delivery and Tumor Detection, *Mini Rev. Med. Chem.*, **2017**, *17*, 1696-1712. (Feb 19, 2016)
22. P.M. Shaibani, H. Etayash, S. Naicker, **K. Kaur**, T. Thundat*, Metabolic Study of Cancer Cells using a pH Sensitive Hydrogel Nanofiber Light Addressable Potentiometric Sensor (NF-LAPS), *ACS Sens.* **2017**, *2*, 151-156. (Dec 29, 2016)
23. R. Soudy, A. Patel, W. Fu, **K. Kaur**, D. MacTavish, D. Westaway, R. Davey, J. Zajac, J. Jhamandas*, Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's Disease, *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, **2017**, *3*, 44-56. (Nov, 2016)

24. H. Etayash, M.F. Khan, **K. Kaur***, T. Thundat*, Microfluidic cantilever detects bacteria and measures their susceptibility to antibiotics in small confined volumes, *Nature Comm.* **2016**, *7*, 12947. (Oct 4, 2016)
25. H. Etayash, A.R. McGee, **K. Kaur**, T. Thundat*, Nanomechanical sandwich assay for multiple cancer biomarkers in breast cancer cell-derived exosomes, *Nanoscale* **2016**, *8*, 15137-41. (Aug 18, 2016)
26. **K. Kaur***, O. Tarassova, R.V. Dangeti, S. Azmi, D. Wishart, L. McMullen, M. Stiles, Characterization of a highly potent antimicrobial peptide microcin N from Uropathogenic Escherichia coli, *FEMS Microbiol. Lett.* **2016**, *11*, 363. (Apr 15, 2016)
27. H. Etayash, K. Jaing, S. Azmi, T. Thundat, **K. Kaur***, Real-time Detection of Breast Cancer Cells Using Peptide-functionalized Microcantilever Arrays, *Sci. Rep. (Nature Publishing Group)*, **2015**, *5*, 13967:1-13. (Oct 5, 2015).
28. K. Jiang, H. Etayash, S. Azmi, S. Naicker, M. Hassanpourfard, P.M. Shaibani, G. Thakur, **K. Kaur,** T. Thundat*, Rapid Label-free Detection of *E. coli* using Antimicrobial Peptide Assisted Impedance Spectroscopy, *Anal. Methods*, **2015**, *7*, 9744-9748. (Aug 25, 2015)
29. H. Etayash, S. Azmi, R. Dangeti, **K. Kaur***, Peptide Bacteriocins – Structure Activity Relationships, *Curr. Top. Med. Chem.*, **2015**, *16*, 220-241. (Aug 12, 2015)
30. H. Trzeciakiewicz, J. Esteves-Villanueva, R. Soudy, **K. Kaur**, S. Martic-Milne*, Electrochemical Characterization of Protein Adsorption onto YNGRT-Au and VLGXE-Au Surfaces, *Sensors*, **2015**, *15*, 19429-19442. (Aug 7, 2015)
31. M. H. Gilzad-Kohan*, **K. Kaur**, and F. Jamali, Synthesis and characterization of a new peptide prodrug of glucosamine with enhanced gut permeability, *PLoS One,* **2015**, *10(5)*, e0126786. (May 15, 2015)
32. S. Azmi, K. Jaing, T. Thundat, **K. Kaur***, Detection of *Listeria monocytogenes* with short peptide fragments from class IIa bacteriocins as recognition elements, *ACS Comb. Sci.,* **2015**, *17*, 156-163. (selected for cover page picture) (Mar 9, 2015)
33. **K. Kaur***, S. Bhattacharjee, R. Pillai, S. Ahmed, S. Azmi, Peptide Arrays for Detecting Naphthenic Acids in Oil Sands Process Affected Water, *RSC Advances*, **2014**, *4*, 60694-60701. (Nov 4, 2014)
34. S. Ahmed, T. Sprules, and **K. Kaur***, Structural similarity between β^3-Peptides synthesized from and β^3-homo-amino acids and L-aspartic acid monomers, *Biopolymers (Peptide Science).* **2014**, *102*, 359-367.
35. N.S.K. Gunda, M. Singh, L. Norman, **K. Kaur**, and S.K. Mitra*, Optimization and characterization of biomolecule immobilization on silicon substrates using (3-aminopropyl)triethoxysilane (APTES) and glutaraldehyde link, *Applied Surface Science. Microdevices,* **2014**, *305*, 522-530.
36. H. Etayash, K. Jaing, T. Thundat, **K. Kaur***, Impedimetric Detection of Pathogenic Gram-Positive Bacteria using An Antimicrobial Peptide from Class IIa Bacteriocins, *Anal. Chem.*, **2014**, *86*, 1693-1700.
37. H. Etayash, L. Norman, T. Thundat, M. Stiles, **K. Kaur***, Surface Conjugated Antimicrobial Peptide Leucocin A Displays High Binding to Pathogenic Gram-positive Bacteria, *ACS Appl. Mater. Interfaces*, **2014**, *6*, 1131-1138.
38. R. Soudy, C. Chen, and **K. Kaur***, Novel Peptide-Doxorubicin Conjugates for Targeting Breast Cancer Cells including the Multidrug Resistant Cells, *J. Med. Chem.,* **2013**, *56*, 7564-7573.

39. M. H. Gilzad-Kohan, **K. Kaur**, and F. Jamali*, The Antiinflammatory Action and Pharmacokinetics of a Novel Di-Peptide Aminosugar, *J. Pharm. Pharm. Sci.,* **2013**, *16*, 279-288.
40. N.S.K. Gunda, M. Singh, Y. Purwar, S.L. Shah, **K. Kaur**, and S.K. Mitra*, Micro-spot with Integrated Pillars (MSIP) for Detection of Dengue Virus NS1, *Biomed. Microdevices,* **2013**, *15*, 959-971.
41. A.S. Mathews, S. Ahmed, M. Shahin, A. Lavasanifar and **K. Kaur***, Peptide modified Polymeric Micelles Specific for Breast Cancer Cells, *Bioconjugate Chem.,* **2013**, *24*, 560-570.
42. K. Bodapati, R. Soudy, H. Etayash, Michael Stiles, and **K. Kaur***, Design, Synthesis and Evaluation of Antimicrobial Activity of N-Terminal Modified Leucocin A Analogues, *Bioorg. Med. Chem.,* **2013**, *21*, 3715-3722.
43. H. Etayash, L. Norman, T. Thundat, **K. Kaur***, Peptide-Bacteria Interactions using Engineered Surface Immobilized Peptides from Class IIa Bacteriocins, *Langmuir*, **2013**, *29*, 4048-4056.
44. A. Sohrabi, P.M. Shaibani, H. Etayash, **K. Kaur**, T. Thundat*, Sustained drug release and antibacterial activity of ampicillin incorporated poly(methyl methacrylate)–nylon6 core/shell nanofibers, *Polymer*, **2013**, *54*, 2699-2705.
45. M. Shahin, R. Soudy, H.M. Aliabadi, N. Kneteman, **K. Kaur**, A. Lavasanifar*, Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity, *Biomaterials* **2013**, *34*, 4089-4097.
46. R. Soudy, S. Ahmed and **K. Kaur***, NGR Peptide Ligands for Targeting CD13/APN Identified through Peptide Array Screening Resemble Fibronectin Sequences, *ACS Comb. Sci.,* **2012**, *14*, 590-599. (selected for cover page picture)
47. M. Shahin, R. Soudy, H. El-Sikhry, J.M. Seubert, **K. Kaur**, A. Lavasanifar*, Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin, *Cancer Lett.,* **2012**, *334*, 284-292.
48. D. Raghuwanshi, V. Mishra, M.R. Suresh, **K. Kaur***, A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles, *Vaccine,* **2012**, *30*, 7292-7299.
49. R. Soudy, L. Wang, and K. Kaur*, Synthetic Peptides derived from the Sequence of a Lasso Peptide Microcin J25 show Antibacterial Activity, *Bioorg. Med. Chem.*, **2012**, *20*, 1794-1800.
50. D. Raghuwanshi, V. Mishra, D. Das, **K. Kaur**,* and M.R. Suresh, Dendritic Cell Targeted Chitosan Nanoparticles for Nasal DNA Immunization against SARS CoV Nucleocapsid Protein, *Mol. Pharmaceutics* **2012**, *9*, 946-956.
51. R. Soudy, A. Gill, T. Sprules, A. Lavasanifar, and **K. Kaur***, Proteolytically Stable Cancer Targeting Peptides with High Affinity for Breast Cancer Cells, *J. Med. Chem.*, **2011**, *54*, 7523-7534.
52. W. Soliman, L.Wang, S. Bhattacharjee, and **K. Kaur***, Structure-activity relationships of an antimicrobial peptide Plantaricin S from two-Peptide class IIb bacteriocins, *J. Med. Chem.* **2011**, *54*, 2399-2408.
53. M. Shahin, S. Ahmed and **K. Kaur**, A. Lavasanifar*, Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel, *Biomaterials* **2011**, *32*, 5123-5133.
54. M. Abbasi, H.M. Aliabadi, E.H. Moase, A. Lavasanifar, **K. Kaur**, R. Lai, C. Doillon, H. Uludağ*, siRNA-Mediated Down-Regulation of P-glycoprotein in a Xenograft Tumor Model in NOD-SCID Mice, *Pharm. Res.* **2011**, *28*, 2516-2529.

55. S. Ahmed, A.S. Mathews, N. Byeon, A. Lavasanifar, **K. Kaur***, Peptide Arrays for Screening Cancer Specific Peptides. *Anal. Chem.,* **2010**, *82*, 7533-7541.
56. W. Soliman, S. Bhattacharjee, and **K. Kaur***, Adsorption of an Antimicrobial Peptide on Self-Assembled Monolayers by Molecular Dynamics Simulation, *J. Phys. Chem. B* **2010**, *114*, 11292-11302.
57. W. Soliman, S. Bhattacharjee, and **K. Kaur***, Interaction of an Antimicrobial Peptide with a Model Lipid Bilayer using Molecular Dynamics Simulation, *Langmuir* **2009**, *25*, 6591-6595.
58. S. Ahmed and **K. Kaur***, The Proteolytic Stability and Cytotoxicity Studies of L-Aspartic Acid and L-Diaminopropionic Acid derived β-Peptides and a Mixed α/β-Peptide, *Chem. Biol. Drug Des.* **2009**, *73*, 545-552.
59. R. Beleid, D. Douglas, N. Kneteman, and **K. Kaur***, Helical peptides derived from lactoferrin bind hepatitis C virus envelope protein E2, *Chem. Biol. Drug Des.* **2008**, *72*, 436-443.
60. **K. Kaur***, T. Sprules, W. Soliman, R. Beleid, S. Ahmed, Right-handed 14-Helix in beta(3)-Peptides from L-Aspartic Acid Monomers, *Biochim. Biophys. Acta* **2008**, *1784*, 658-665.
61. W. Soliman, S. Bhattacharjee, and **K. Kaur***, Molecular dynamics simulation study of interaction between a class IIa bacteriocin and its immunity protein, *Biochim. Biophys. Acta* **2007**, *1774*, 1002-1013.
62. S. Ahmed, R. Beleid, T. Sprules, and **K. Kaur***, Solid-phase synthesis and CD spectroscopic investigations of novel β-peptides from L-aspartic acid and β-amino-L-alanine, *Org. Lett.* **2007**, *9*, 25-28.
63. L.J. Gursky, N.I. Martin, D.J. Derksen, M.J. Van Belkum, **K. Kaur**, J.C. Vederas, M.E. Stiles, L.M. McMullen*, Production of piscicolin 126 by *Carnobacterium maltaromaticum* UAL26 is controlled by temperature and induction peptide concentration, *Arch. Microbiol.* **2006**, *186*, 317-325.
64. **K. Kaur**, L.C. Andrew, D.S. Wishart, and J.C. Vedera*s**, Dynamic relationships among type IIa bacteriocins: Temperature effects on antimicrobial activity and on structure of the C-terminal amphipathic α-helix as a receptor binding region, *Biochemistry* **2004**, *43*, 9009-9020.
65. N.R. Silvaggi, **K. Kaur**, S.A. Adediran, R.F. Pratt*, and J.A. Kelly*, Toward better antibiotics: Crystallographic studies of a novel class of DD-peptidase/β-lactamase inhibitors, *Biochemistry* **2004**, *43*, 7046-7053.
66. **K. Kaur**, S.A. Adediran, M.J.K. Lan, and R.F. Pratt*, Inhibition of β-lactamases by monocyclic acyl phosph(on)ates, *Biochemistry* **2003**, *42*, 1529-1536.
67. **K. Kaur**, M.J.K. Lan, and R.F. Pratt*, Mechanism of inhibition of the class C β-lactamase of *Enterobacter cloacae* P99 by cyclic acyl phosph(on)ates: Rescue by return, *J. Am. Chem. Soc.* **2001**, *123*, 10436-10443.
68. **K. Kaur** and R.F. Pratt*, Mechanism of reaction of acyl phosph(on)ates with the β-lactamase of *Enterobacter Cloacae* P99, *Biochemistry* **2001**, *40*, 4610-4621.
69. R.G. Salomon*, **K. Kaur**, and E. Batyreva, Isolevuglandin-protein adducts in oxidized low density lipoprotein and human plasma: A strong connection with cardiovascular disease, *Trends Cardiovasc. Med.,* **2000**, *10*, 53-59.
70. R.G. Salomon*, **K. Kaur**, E. Podrez, H.F. Hoff, A.V. Krishinsky, L.M. Sayre, HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from

patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques, *Chem. Res. Toxicol.,* **2000**, *13(7)*, 557-564.

71. R.G. Salomon*, E. Batyreva, **K. Kaur**, D. Sprecher, M.J. Schreiber, J.W. Crabb, M.S. Penn, A.M. DiCorleto, S.L. Hazen, E.A. Podrez, Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway, *Biochim. Biophys. Acta,* **2000**, *1485(2-3)*, 225-235.
72. R.G. Salomon*, W. Sha, C. Brame, **K. Kaur**, G. Subbanagounder, J. O'Neil, H.F. Hoff and L.J. Roberts II, Protein adducts of iso[4]levuglandin E_2, a product of the isoprostane pathway, in oxidized low density lipoprotein, *J. Biol. Chem.,* **1999**, *274(29)*, 20271-20280.
73. **K. Kaur**, R.G. Salomon*, J. O'Neil, and H.F. Hoff, Carboxyalkyl pyrroles in human plasma and oxidized low density lipoproteins, *Chem. Res. Toxicol.,* **1997**, *10(12)*, 1387-1396.
74. R.G. Salomon*, G. Subbanagounder, J. O'Neil, **K. Kaur**, M.A. Smith, H.F. Hoff, G. Perry, and V.M. Monnier, Levuglandins E_2-protein adducts in human plasma and vasculature, *Chem. Res. Toxicol.,* **1997**, *10(5)*, 536-545.
75. L.M. Sayre, W. Sha, G. Xu, **K. Kaur**, D. Nadkarni, G. Subbanagounder, and R.G. Salomon*, Immunochemical evidence supporting 2-pentylpyrrole formation on proteins exposed to 4-hydroxy-2-nonenal, *Chem. Res. Toxicol.,* **1996**, *9(7)*, 1194-1201.
76. Y.D. Vankar*, G. Kumaravel, I. Bhattacharya, P.S. Vankar, and **K. Kaur**, Reactions of 2-phenylthio-2-cycloalkenones and 2-[phenyl(thiomethyl)]-2-cycloalkenones: Synthesis of some useful chiral and achiral intermediates, *Tetrahedron,* **1995**, *51*, 4829-4840.

BOOK CHAPTERS [n=4]

77. H. Etayash, T. Thundat, **K. Kaur***, Bacterial Detection using Peptide-based Platform and Impedance Spectroscopy, in *Methods Mol. Biol.*, Biosensors and Biodetection: Methods and Protocols, Second Edition, Edited by Avraham Rasooly and Ben Prickril, **2017**, Vol 1572, 113-124.
78. **K. Kaur*,** S. Ahmed, R. Soudy, S. Azmi, Screening Peptide Array Library for the Identification of Cancer Cell Binding Peptides, in *Methods Mol. Biol.*, Peptide Libraries, Edited by R. Derda, Springer, **2015**, Vol 1248, 239-247.
79. S. Bhattacharjee and **K. Kaur**, van der Waals and Casimir Interactions, in *Microfluidics and Nanofluidics Handbook*, Edited by S. K. Mitra and S. Chakraborty, CRC Taylor and Francis, **2011**.
80. **K. Kaur*,** D. Das, M. Suresh, Protein-Protein Interactions, in *Preclinical Development Handbook*, ADME and Biopharmaceutical Properties, Edited by Shayne C. Gad, John Wiley & Sons, Inc., NJ, USA **2008**, pp 87-116.

PATENT [n=5]

1. Kamaljit Kaur, Phi-Phung Than, EGFR targeting peptide-doxorubicin conjugate with specific toxicity to cancer cells, U.S. Patent Application No. 18/452,405 filed Aug 18, **2023**.
2. Sun Yang, Kamaljit Kaur, Shirley Tong, A Small Peptide Increases Drug Delivery in Human Melanoma Cells, U.S. Patent Application No. 18/330,748 filed Jun 7, **2023**.
3. Kamaljit Kaur and Hanieh Hossein-Nejad-Ariani, Rapid Selective Detection of Bacteria, U.S. Patent Application Publication No. US 2020/0347431 A1, Nov 5, **2020**.

4. Jack Jhamandas, Rania Soudy, Kamaljit Kaur, When Fu, David, Mactavish, Aarti Patel, Brain Penetrant Amylin Receptor Based Peptides for Alzheimer's Disease, U.S. Patent No. US 10,766,940 B2, Sep 8, **2020**.
5. Fahkreddin Jamali, Kamaljit Kaur, Mohammadhossien Gilzad, Glucosamine Pro-drugs, U.S. Patent Application Publication No. US 2013/0196897 A1, Aug 01, **2013**.

INVITED SPEAKER [n=35]

1. Peptide-drug conjugates for selective uptake by triple-negative breast cancer, ACS Spring 2025 Meeting and Exposition, San Diego, California, Mar 23rd, **2025**. (Symposium: Peptide Conjugates: An Emerging New Era in Targeted Therapy, Track: Division of Medicinal Chemistry, Organizer: Nicholas Meanwell and Paul Scola, Bristol-Myers Squibb, and Mihirbaran Mandal, Merck).
2. Peptide-drug conjugates targeting cell-surface keratin 1 for treatment of triple-negative breast cancer, ACS Spring 2024 Meeting and Exposition, New Orleans, Louisiana, Mar 18th, **2024**. (Symposium: Women's Health, Track: Division of Medicinal Chemistry, Organizer: Hasan Khan, Abbvie).
3. Keratin 1 – a phage display-identified target for peptide-drug conjugate, DAVA Think Tank on Antibody Drug Conjugates & Bispecifics, Victoria, British Columbia, Canada, Mar 16th, **2024**. (Session: ADC Targets in Preclinical Development, Organizer: DAVA Oncology)
4. A novel peptide-drug conjugate targeting EGFR, DAVA Think Tank on Antibody Drug Conjugates & Bispecifics, Victoria, British Columbia, Canada, Mar 15th, **2024**. (Session: Non-Antibody Drug Conjugates, Organizer: DAVA Oncology)
5. Peptide-drug conjugates with high selectivity for triple-negative breast cancer, 14th AFMC International Medicinal Chemistry Symposium 2023, Seoul, Korea, Jun 28th, **2023**.
6. Improved Efficacy of Chemotherapy with Peptide-Drug Conjugates, School of Chemistry and Materials Science Seminar Series, Rochester Institute of Technology (RIT), Rochester, NY, USA, Mar 29th, **2022**.
7. Peptide-drug conjugates: A novel modality for triple-negative breast cancer treatment, ACS Spring 2022 (Mar 20-24), Mar 21st, **2022**. (Symposium: Drugging the Undruggable, Track: Division of Medicinal Chemistry, Organizer: James Fells and Jennifer Hickey, C. Huang, Merck Research Laboratories, and Dian Su, Genentech).
8. Peptide-drug conjugates for improved efficacy of chemotherapy for treatment of triple-negative breast cancer, ACS Spring 2021 (Apr 5-16), VIRTUAL, Apr 12th, **2021**. (Symposium: Peptide-Drug Conjugates: A Novel Modality in Organic and Medicinal Chemistry, Track: Division of Organic Chemistry, Organizer: Dr. C. Huang, Merck Research Laboratories, Boston, MA).
9. Peptide-Drug Conjugates for Treatment of Triple-Negative Breast Cancer, Department Seminar, Department of Biochemistry, City University of New York (CUNY), New York, USA, Nov 30th, **2020**.
10. Breast Cancer Detection and Treatment with Engineered Peptides, Association of Official Analytical Communities (AOAC)-SCS Conference in partnership with United States Pharmacopeia (USP), Irvine, California, USA, Dec 04, **2019**.

11. TNBC Detection and Treatment with Engineered Peptides and Peptide-drug Conjugates, Breast DOT Meeting, University of California-Irvine (UCI) Medical Center, Orange, California, USA, Oct 29, **2019**.
12. Peptide Engineering for Targeting Pathogenic Bacteria and Cancer Cells, College of Osteopathic Medicine, Western University of Health Sciences, Pomona, California, USA, Dec 14, **2018**
13. Microcantilever arrays functionalized with a breast cancer targeting peptide as detection platforms for circulating tumor cells, Chemistry & Biology of Peptides, Gordon Research Conference, Ventura, California, USA, February 21 – 26, **2016**.
14. Peptide-functionalized microcantilever arrays as detection platforms for circulating tumor cells in human blood, PACIFICHEM 2015, Honolulu, Hawaii, USA, Dec 19, **2015**.
15. Peptide-based Platforms as Biosensors for Bacteria and Circulating Tumor Cells, School of Pharmacy, Chapman University, Irvine, California, USA, Apr 01, **2015**.
16. Peptide Engineering for Targeting Pathogenic Bacteria and Cancer Cells, Department of Chemistry, Indian Institute of Technology Delhi, New Delhi, India, Aug 12, **2014**.
17. The Power of Peptides in Cancer Treatment and other Biomedical Applications, Edmonton Biology and Chemistry Regional's Annual Conference, Edmonton, Alberta, Canada, May 02, **2014**.
18. Peptide Engineering for Biomedical Applications, Canadian Federation of University Women, Edmonton, Alberta, Canada, 18th November **2013**.
19. Engineering Proteolytically Stable Peptides for Cancer Targeting, 3rd Euro-India International Conference on Nanomedicine and Tissue Engineering, Kottayam, Kerala, India, 9th August **2013** (Symposium: Nanotechnology for Cancer).
20. Peptide Engineering for Food Safety and Biomedical Applications, Department of Chemical Technology, University of Calcutta, Calcutta, India, 7th August **2013**.
21. Peptide Engineering for Targeting Pathogenic Bacteria and Cancer Cells, Department of Pharmaceutical Sciences, University of California, Irvine, California, USA, 26th June **2013**.
22. Peptide Engineering for Improving the Outcome of Current Therapeutics and Diagnostics for Cancer, 3rd Western Canadian Medicinal Chemistry Workshop, Saskatoon, Saskatehewan, Canada, September 28-30, **2012**.
23. Peptides for Targeting Anticancer Drugs Specifically to the Cancer Site, 95th Canadian Chemistry Conference and Exhibition, Calgary, Alberta, Canada, May 30, **2012**. (Symposium: Antimicrobial and Host-defense Peptides).
24. Peptide Engineering for Targeting Cancer Cells, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, 11th Nov **2011**.
25. Engineering Small Peptides for Cancer Drug Delivery and Diagnostics, Department of Chemistry, New York University, New York, USA, 7th Nov **2011**.
26. Engineering Biologically Active Peptides, Department of Chemistry, Wesleyan University, Connecticut, USA, 4th Nov **2011**.
27. Engineering Proteolytically Stable Breast Cancer Targeting Peptides, 94th Canadian Chemistry Conference and Exhibition, Montreal, Quebec, Canada, June 5- 9, **2011**. (Symposium: Peptide Science).

28. Peptide Arrays for Screening Cancer Targeting Agents, International Science and Technology Partnership (ISTP) Indo-Canadian Workshop, Joint Indo-Canadian Meeting on Development of Low-Cost Lab-on-a-chip Medical Devises for Health Monitoring, IIT Bombay, India, January 7-11, **2011**.
29. Cancer Targeting Peptides from Peptide Arrays, PACIFICHEM, Honolulu, Hawaii, USA, Dec 17, **2010**. (Symposium: Protein, Peptide, and Peptidomimetics Design by the International Chemical Congress of Pacific Basin Societies).
30. Peptide Arrays for Selecting Cancer Targeting Peptides, 93rd Canadian Chemistry Conference and Exhibition, Toronto, ON, Canada, May 29- June 2, **2010**. (Symposium: Peptides and Their Pharmaceutical Relevance, organized by Eli Lilly Inc. Canada).
31. Design and Synthesis of Novel β-peptides as Entry Inhibitors of Hepatitis C Virus, 89th Canadian Chemistry Conference and Exhibition, Halifax, NS, Canada, May 28, **2006**. (Symposium: Peptide Science).
32. Peptides as therapeutics: Simulation of peptide-peptide interactions, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, November **2005**.
33. Alternatives to Antibiotics: Structure & Mechanism of Antimicrobial Peptides from Lactic Acid Bacteria, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, October **2003**.
34. Mechanism of Inhibition of *Enterobacter cloacae* P99 β-Lactamase by Cyclic Acyl Phosphate, Department of Chemistry, Wesleyan University, Middletown, Connecticut, October **2000**.
35. Two-faced Substrates/Inhibitiors of Class C β-Lactamase of *Enterobacter cloacae* P99, Department of Chemistry, Wesleyan University, Middletown, Connecticut, September **1999**.

CONFERENCE PRESENTATIONS [n=96]

(Bold: presenter, underlined: trainee names under my supervision, *: corresponding author)

1. **Shih-Jing yao**, Keon Jafari, Kamaljit Kaur*, Biodistribution of a peptide-drug conjugate targeting triple-negative breast cancer in mice, ACS Spring 2025 Meeting and Exposition, San Diego, CA, USA, Mar 23-27, 2025.
2. **Mahta Khojasteh** and Kamaljit Kaur*, Role of cell-surface receptors EphA2 and Trop2 in cancer treatment, CPhA Western Pharmacy Exchange, Las Vegas, NV, April 19-20, 2024.
3. **Sarah Abib** and Kamaljit Kaur*, The role of CD19 receptor in making tumor selective therapy, CPhA Western Pharmacy Exchange, Las Vegas, NV, April 19-20, 2024.
4. **Mena Eskandar** and Kamaljit Kaur*, The role of LRP-1 receptor in cancer treatment, CPhA Western Pharmacy Exchange, Las Vegas, NV, April 19-20, 2024.
5. **K. Kaur***, Cell-Selective Peptides for Targeting Triple-Negative Breast Cancer and Melanoma, ACS Fall 2023, San Francisco, CA, USA, August 13-17, 2023.
6. **K. Kaur***, Targeting triple-negative breast cancer with small peptide ligands, Chemistry & Biology of Peptides, Gordon Research Conference, Oxnard, California, USA, Oct 30 – Nov 04, 2022.
7. **Phi-Phung Than**, K. Kaur*, Synthesis and evaluation of a novel peptide-doxorubicin conjugate for targeted uptake by triple-negative breast cancer cells, ACS Fall 2022 Meeting and Exposition, Chicago, IL, USA, August 21-25, 2022.

8. **K. Kaur***, Targeting triple-negative breast cancer (TNBC) and melanoma with small peptide ligands, 27th American Peptide Symposium, Whistler, BC, Canada, June 11-16, 2022. (Session: Peptides in the Clinic)
9. **M. Law**, X. Xu, B. Kaur, S. Shaut, J. Evans, C.G. McGrath, M. Kandwal, M.C. Ferran, K. Kaur, H.F. Schmitthenner*, Solid phase synthesis of molecularly targeted agents for breast cancer imaging, ACS Spring 2022, San Diego, CA, USA, March 20-24, 2022.
10. **A. Saghaeidehkordi** and K. Kaur*, Design and synthesis of a peptide-aldoxorubicin conjugate to target triple negative breast cancer, ACS National Meeting and Exposition, San Diego, CA, USA, August 25-29, 2019.
11. **E. Ziaei** and K. Kaur*, Peptide-doxorubicin conjugate for specific uptake by triple negative breast cancer cells, ACS National Meeting and Exposition, San Diego, CA, USA, August 25-29, 2019.
12. **K. Kaur***, Peptide-based biosensor for detection of Listeria monocytogenes- Can Bacteriocins make it?, 26th American Peptide Symposium, Monterey, CA, USA, June 22-27, 2019.
13. **K. Kaur***, Antimicrobial Peptide-based Platform with Fluorescent Gold Nanoclusters for Selective Detection of *Listeria monocytogenes*, 2018 Materials Research Society (MRS) Fall Meeting and Exhibit, Hynes Convention Center, Boston, Massachusetts, USA, Nov 25-30, 2018.
14. **E. Althagafi**, H. Hossein-Nejad-Ariani, and K. Kaur*, Engineering Cyclic Analogue of a Cancer Targeting Peptide GE11 for Enhanced Proteolytic Stability, 99th American Association for the Advancement of Science (AAAS) Annual meeting, Pomona, California, USA, June 13, 2018.
15. **A. Saghaeidehkordi**, K. Kaur*, Synthesizing peptide-doxorubicin conjugates to target triple negative breast cancer, Chemistry & Biology of Peptides, Gordon Research Conference, Ventura, California, USA, February 11 – 16, 2018.
16. **I. Paiva**, R. Soudy, A. Soleimani, Y.H. Huang, K. Kaur, Afsaneh Lavasanifar*, Near-infrared optical imaging of c18-DK decapeptide in an orthotopic breast cancer mouse model, Controlled Release Society Annual Meeting & Exposition, Boston, USA, July 16-19, 2017.
17. **K. Kaur***, R. Soudy, A. Lavasanifar, Breast cancer targeting peptides and peptide-drug conjugates for increased therapeutic efficacy of current chemotherapeutic drugs against triple negative breast cancer, 25th American Peptide Symposium, Whistler, BC, Canada, June 17-22, 2017.
18. **H. Hossein-Nejad-Ariani**, T. Kim, K. Kaur*, Application of leucocin A peptide and gold nanoclusters for selective detection of *Listeria monocytogenes*, 25th American Peptide Symposium, Whistler, BC, Canada, June 17-22, 2017.
19. E. Ziaei, **H. Hossein-Nejad-Ariani**, K. Kaur*, Doxorubicin conjugate for targeting breast cancer cells, 25th American Peptide Symposium, Whistler, BC, Canada, June 17-22, 2017.
20. **K. Kaur**,* M. Stiles, R. Dangeti, Engineering anti-listerial Class IIa bacteriocin Leucocin A for application in food storage, PACIFICHEM 2015, Honolulu, Hawaii, USA, Dec 15-20, 2015.
21. **S. Bhattacharjee**, K. Kaur*, Peptide array platform for detecting the presence of naphthenic acids in petroleum process affected water, PACIFICHEM 2015, Honolulu, Hawaii, USA, Dec 15-20, 2015.
22. **K. Jiang**, H. Etayash, S. Azmi, P.M. Shaibani, S. Naicker, K. Kaur, T. Thundat, Rapid Detection of Pathogenic Bacteria with Antimicrobial Peptide assisted Microcantilever Sensor Array, 2015 Materials Research Society (MRS) Fall Meeting, Boston, Massachusetts, Nov 29-Dec 4, 2015.
23. **H. Etayash**, K. Jiang, S. Azmi, T. Thundat, and K. Kaur*, Peptide-based Microcantilever Sensor Arrays for Real-time Detection of Breast Cancer Cells, 24th American Peptide Symposium, Orlando, Florida, USA, June 20-25, 2015. (poster, selected as TOP 20 in 430 posters)

24. **R. Soudy**, K. Bahadorani, K. Kaur*, Conjugate of Microcin J25 with Cancer Targeting Peptide Displays Specific Cytotoxicity against Breast Cancer Cells, 24th American Peptide Symposium, Orlando, Florida, USA, June 20-25, 2015. (poster, selected as TOP 20 in 430 posters)
25. **R. Soudy**, W. Fu, D. MacTavish, K. Kaur, J. Jhamandas*, Development of Novel Therapeutics for Alzheimer's Disease: Brain Penetrant Amylin Receptor-based Peptides, 24th American Peptide Symposium, Orlando, Florida, USA, June 20-25, 2015.
26. **K. Bahadorani**, R. Soudy, K. Kaur*, Identification of Target Receptor Protein for P160-based Cancer Targeting Peptides, Canadian Society for Pharmaceutical Sciences (CSPS) 2015 Annual Symposium**,** Toronto, ON, Canada, May 26-28, 2015.
27. **K. Kaur***, T. Thundat, M. Stiles, H. Etayash, K. Jiang, Engineering anti-listerial Class IIa bacteriocin, Leucocin A, for different applications, Antimicrobial Peptides, Gordon Research Conference, Lucca (Barga), Italy, May 3–8, 2015.
28. **K. Jiang**, H. Etayash, S. Azmi, G. Thakur, S. Naicker, K. Kaur*, T. Thundat*, Label-free rapid detection of pathogens with antimicrobial peptide assisted impedance spectroscopy, 2015 Materials Research Society (MRS) Spring Meeting, San Francisco, California, Apr 6-10, 2015.
29. **K. Kaur***, Antimicrobial peptide-based platforms as biosensors for pathogenic bacteria, 4th International Symposium on Antimicrobial Peptides, Lorient, France, June 4-6, 2014.
30. **S. Azmi**, K. Jiang, M. Stiles, T. Thundat, and K. Kaur*, Sorting of High Bacterial Affinity Peptide Fragments from Full Length Bacteriocins for Application in Bacterial Detection, 97th Canadian Chemistry Conference and Exhibition, Vancouver, B.C., Canada, Jun 1-5, 2014.
31. **Y. Raghuwanshi**, R. Soudy, H. Yu, and K. Kaur*, Novel Peptide-drug Conjugates for Targeted Drug Delivery to Breast Cancer Cells, 97th Canadian Chemistry Conference and Exhibition, Vancouver, B.C., Canada, Jun 1-5, 2014.
32. **H. Yu**, Y. Raghuwanshi and K. Kaur*, Using Peptides to Synthesize Cancer Targeting Compounds, Canadian Society for Pharmaceutical Sciences (CSPS) 2014 Annual Conference, Montreal, QC, Canada, June 10-13, 2014.
33. **K. Kaur***, R. Soudy, Y. Raghuwanshi, M. Shahin, A. Lavasanifar, Novel Peptide-drug Conjugates for Breast Cancer Targeted Delivery of Doxorubicin, 2014 AAPS National Biotechnology Conference, San Diego, 19-21 May 2014. (Symposium: Drug Delivery-Biotechnology Products)
34. **K. Kaur***, T. Thundat, H. Etayash, K. Jiang, Detection of Pathogenic Gram-positive Bacteria using Antimicrobial Peptide-based Platforms, Chemistry & Biology of Peptides, Gordon Research Conference, Ventura, California, February 23 – 28, 2014.
35. **Sanela Martic***, Kamaljit Kaur*, Rania Soudy, Electrochemical Screening of Peptides for targeting CD13, 224th ECS Meeting, San Francisco, CA, USA, Oct 27- Nov 1, 2013.
36. **K. Kaur***, R. Soudy, M. Shahin, A. Lavasanifar, Engineered peptides for breast cancer targeted delivery of doxorubicin, 87th ACS Colloid & Surface Science Symposium, Riverside, CA, USA, June 23-26, 2013.
37. **Waleed Mohammed-Saeid**, Jackson Chitanda, Kamaljit Kaur, Rania Soudy, Ronald Verrall, Ildiko Badea*, Targeted Gemini Surfactant-Based Nucleic Acid Delivery for Melanoma Gene Therapy, Canadian Society for Pharmaceutical Sciences (CSPS) 2013 Annual Symposium**,** Vancouver, BC, Canada, June 11-14, 2013.

38. N.S.K. Gunda, M. Singh, Y. Purwar, S. L. Shah, K. Kaur, **S.K. Mitra***,, Microspot with integrated pillars (MSIP) for the detection of Dengue NS1 virus, 223th Electrochemical Society (ECS) Meeting, Toronto, Ontario, Canada, May 12-16, 2013.
39. **H. Etayash**, L. Norman, T. Thundat*, K. Kaur*, Class IIa Bacteriocins towards the Detection of Foodborne Pathogens, Surface Canada 2013, London, ON, Canada, May 7-10, 2013.
40. **R. Soudy**, S. Ahmed and K. Kaur*, Design and screening of NGR tripeptide library for the discovery of new aminopeptidase N ligand with improved binding affinity, 3rd Western Canadian Medicinal Chemistry Workshop, Saskatoon, SK, Canada, September 28-30, 2012.
41. **H. Etayash**, W. Soliman, and K. Kaur*, Peptide-peptide interaction of lactococcin G class IIb two-peptide bacteriocin, 32nd European Peptide Symposium, Greece, Sep 2-7, 2012.
42. **H. Etayash**, L. Norman, T. Thundat*, K. Kaur*, The detection of Listeria monocytogenes using a surface tethered c-termnal 24 amino acid Leucocin A fragment, 32nd European Peptide Symposium, Greece, Sep 2-7, 2012.
43. N.S.K. Gunda, M. Singh, D. Sarkar, P.R. Waghware, S.S. Roy, K. Kaur, **S.K. Mitra***, Integrated microfluidic based immunosensor platforms for rapid detection of biomolecules, Colloids and Nanomedicine 2012, Amsterdam, Netherlands, 15-17 July 2012.
44. **K. Kaur***, Peptide Arrays on Cellulose Membranes for Screening Cancer Targeting Peptides, International Conference on Nanochannels, Microchannels and Minichannels (ICNMM), ASME 2012, Rio Grande, Puerto Rico, July 8-12, 2012. (Symposium: Interfacial Phenomena at Micro and Nanoscale)
45. **K. Kaur*** and S. Bhattacharjee, Molecular Dynamics Simulations to Study Adsorption of an Antimicrobial Peptide on Self-Assembled Monolayers, International Conference on Nanochannels, Microchannels and Minichannels (ICNMM), ASME 2012, Rio Grande, Puerto Rico, July 8-12, 2012. (Symposium: MD Simulation of Microscale and Nanoscale Phenomena)
46. **C. Chen**, R. Soudy and K. Kaur*, Using Peptides to Create Cancer Targeting Compounds, Canadian Society for Pharmaceutical Sciences (CSPS) 2012 Annual Symposium, Toronto, ON, Canada, June 12-15, 2012.
47. **S. Ahmed**, A. Stella, A. Lavasanifar, and K. Kaur*, Engineering Peptide-Nanoconjugates for Breast Cancer Targeting, 95th Canadian Chemistry Conference and Exhibition, Calgary, Alberta, Canada, May 26-30, 2012.
48. **M. Singh**, N. Gunda, K. Kaur and S. Mitra*, Bioconjugation: Covalent Immobilization on Silane Monolayer for Microfluidics Applications, 95th Canadian Chemistry Conference and Exhibition, Calgary, Alberta, Canada, May 26-30, 2012.
49. **H. Etayash**, W. Soliman and K. Kaur*, Peptide-Peptide Interaction Among the Class IIb Two-peptide Bacteriocin, 95th Canadian Chemistry Conference and Exhibition, Calgary, Alberta, Canada, May 26-30, 2012.
50. **R. Soudy**, L. Wang and K. Kaur*, Synthetic Antimicrobial Peptide Sequences Derived from the Sequence of Lasso Peptide Microcin J25, 95th Canadian Chemistry Conference and Exhibition, Calgary, Alberta, Canada, May 26-30, 2012.
51. **M. Shahin**, R. Soudy, K. Kaur, A. Lavasanifar*, Engineered peptides for breast tumor targeted delivery of doxorubicin by stealth liposomal formulations: The effect of ligand density, 12th European Symposium on Controlled Drug Delivery, Egmond aan Zee, Netherlands, April 4-6, 2012.

52. M.G. Kohan, K. Kaur, and **F. Jamali***, Glucosamine from nutraceutical to pharmaceutical: A novel peptide pro-drug with increased bioavailability, 2011 AAPS Annual Meeting and Exposition, Washington, DC, USA, Oct 23-27, 2011.
53. **R. Soudy**, A. Gill, K. Kaur*, Proteolytically Stable Breast Cancer Targeting Decapeptides, 22nd American Peptide Symposium, San Diego, CA, USA, June 25-30, 2011.
54. **K. Bodapati**, R. Soudy, K. Kaur*, Design, Synthesis and Evaluation of Antimicrobial Peptide Leucocin A by Native Chemical Ligation, A Joint Conference of the Canadian Society of Pharmaceutical Sciences (CSPS), The Canadian Society of Pharmacology & Therapeutics, Controlled Release Society, Montreal, Quebec, Canada, May 24-27, 2011.
55. **M. H. Gilzad-Kohan**, K. Kaur, and F. Jamali*, From nutraceutical to pharmaceutical: A novel peptide pro-drug of glucosamine with increased bioavailability, A Joint Conference of the Canadian Society of Pharmaceutical Sciences (CSPS), The Canadian Society of Pharmacology & Therapeutics, Controlled Release Society, Montreal, Quebec, Canada, May 24-27, 2011.
56. **K. Kaur***, Potent bactericidal peptides based on the class IIb bacteriocin, plantaricin S, PACIFICHEM, Honolulu, Hawaii, USA, Dec 15-20, 2010.
57. **K. Bodapati** and K. Kaur*, Design, Synthesis and Evaluation of Potent Antimicrobial Peptide (Leucocin A) Analogues with a Disulfide Bridge Replaced by β-Turn Sequence, 2nd Western Canadian Medicinal Chemistry Workshop, Saskatoon, SK, Canada, September 24-26, 2010.
58. **K. Kaur***, Peptide Arrays for Screening Cancer Cell binding Peptides, 2nd Western Canadian Medicinal Chemistry Workshop, Saskatoon, SK, Canada, September 24-26, 2010.
59. **R. Soudy**, L. Wang, M. Stiles, and K. Kaur*, Design, Synthesis, and Antibacterial Activity of Microcin J25 Analogues, 93rd Canadian Chemistry Conference and Exhibition, Toronto, ON, Canada, May 29- June 2, 2010.
60. **W. Soliman**, L. Wang, M. Stiles, and K. Kaur*, Design and Synthesis of Potent Bactericidal Peptides Based on the Class IIb Bacteriocin Plantaricin S, 93rd Canadian Chemistry Conference and Exhibition, Toronto, ON, Canada, May 29- June 2, 2010.
61. **W. Soliman**, S. Bhattacharjee, and K. Kaur*, Molecular Dynamics Simulations to Study Interaction between a Class IIa Bacteriocin and Model Lipid Bilayer, 93rd Canadian Chemistry Conference and Exhibition, Toronto, ON, Canada, May 29- June 2, 2010.
62. **K. Kaur***, S. Ahmed, A. Stella, and A. Lavasanifar, Cancer Specific Peptides from Peptide Arrays, Peptides, Chemistry & Biology of, Gordon Research Conference, Ventura, California, February 28 - March 5, 2010.
63. **K. Kaur*** Promise of L-Aspartic Acid and L-Diaminopropionic Acid Derived β-Peptidic Oligomers as Pharmaceutical Candidates, 92nd Canadian Chemistry Conference and Exhibition, Hamilton, ON, Canada, May 30- June 3, 2009.
64. **S. Ahmed** and K. Kaur*, Engineering Peptides Based on P160 and NGR Sequences as Cancer Targeting Agents, 92nd Canadian Chemistry Conference and Exhibition, Hamilton, ON, Canada, May 30- June 3, 2009.
65. **S. Ahmed**, K. Kaur*, T. Sprules, R. Beleid, Novel β-Peptides from L-Aspartic Acid and β-Amino-L-Alanine: Synthesis, Solution Conformation, Stability, and Cytotoxicity Studies, 91st Canadian Chemistry Conference and Exhibition, Edmonton, AB, Canada, May 24-28, 2008.

66. **S. Ahmed** and K. Kaur*, Peptide and Peptidomimetic Approaches for Developing Cancer Targeting Agents, 91st Canadian Chemistry Conference and Exhibition, Edmonton, AB, Canada, May 24-28, 2008.
67. **R. Beleid**, K. Kaur*, D. Douglas, N. Kneteman, Design, Synthesis, and Evaluation of Peptide-based HCV Entry Inhibitors, 91st Canadian Chemistry Conference and Exhibition, Edmonton, AB, Canada, May 24-28, 2008.
68. **W. Soliman**, K. Kaur*, S. Bhattacharjee, Molecular Dynamics Simulation of the Interaction of Peptides with Nanoscale Chemical Heterogeneities on a Planar Substrate, 91st Canadian Chemistry Conference and Exhibition, Edmonton, AB, Canada, May 24-28, 2008.
69. **W. Soliman** and K. Kaur*, Interaction between Class IIa Bacteriocins and a Bacterial Cell Membrane Model: A Molecular Dynamics Simulation Study, 91st Canadian Chemistry Conference and Exhibition, Edmonton, AB, Canada, May 24-28, 2008.
70. **W. Soliman**, S. Bhattacharjee, K. Kaur*, Interaction between Class IIa Bacteriocins and Zwitterionic/Anionic Lipid Bilayer: A Molecular Dynamics Simulation Study, 11th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting, Banff, AB, Canada, May 22-25, 2008.
71. **M. Shahin**, Z. Ma, S. Ahmed, K. Kaur, A. Lavasanifar*, Peptide decorated polymeric micelles for selective intracellular drug delivery to metastatic breast cancer cells, 11th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting, Banff, AB, Canada, May 22-25, 2008.
72. **M.H.G Kohan**, A. Aghazadeh-Habashi, K. Kaur, F. Jamali*, Synthesis of a novel glucosamine-amino acid derivative and assessment of its stability and gastrointestinal absorption through the rat everted gut, 11th Canadian Society for Pharmaceutical Sciences (CSPS) Annual Meeting, Banff, AB, Canada, May 22-25, 2008.
73. **K. Kaur***, S. Ahmed, R. Beleid, T. Sprules, Conformational and stability studies of novel β-peptides from L-aspartic acid and □-amino-L-alanine, 234th ACS National Meeting and Exposition, Boston, August 19-23, 2007.
74. **K. Kaur***, W. Soliman, S. Bhattacharjee, Interaction of a type IIa bacteriocin with lipid bilayer and its immunity protein: A molecular dynamics simulation study, 234th ACS National Meeting and Exposition, Boston, August 19-23, 2007.
75. **K. Kaur***, W. Soliman, S. Bhattacharjee, Interaction between a peptide and SAM patterned surface with different functional groups by molecular dynamics simulation, 234th ACS National Meeting and Exposition, Boston, August 19-23, 2007.
76. **S. Ahmed**, R. Beleid, T. Sprules, and K. Kaur*, Novel β-Peptides from L-Aspartic Acid and β-Amino-L-Alanine: Solution Conformation and Stability Studies, 20th American Peptide Society Symposium, Montréal, Quebec, Canada, June 26-30, 2007.
77. **R. Beleid**, D. Douglas, N. Kneteman, and K. Kaur*, Lactoferrin Derived Peptides Possess Binding Activity to HCV-E2, 20th American Peptide Society Symposium, Montréal, Quebec, Canada, June 26-30, 2007.
78. **K. Kaur***, E.T. Wong, and S. Bhattacharjee, Molecular Dynamics Simulations Employing an Ensemble of Peptides, 89th Canadian Chemistry Conference and Exhibition, Halifax, NS, Canada, May 27-31, 2006.
79. **K. Kaur***, W. Soliman, Molecular Dynamics Simulations of Interaction between Carnobacteriocin B2, a Type IIa Bacteriocin and its Immunity Protein, 89th Canadian Chemistry Conference and Exhibition, Halifax, NS, Canada, May 27-31, 2006.

80. **K. Kaur**, S. Marcus, K. Kawulka, and J.C. Vederas*, Role of Key Amino Acid Residues from the Phosphotransferase System (PTS) Mannose Permease Receptor Protein in the Mechanism of Action of Class IIa Bacteriocins, PACIFICHEM, Honolulu, Hawaii, USA, December 15-20, 2005.
81. **K. Kaur*** Dynamic Effects on Peptide Structure: Molecular Dynamics Simulations of a Peptide Employing Ensemble of Peptides, The 2005 International Conference on MEMS, NANO, and Smart Systems, Banff, AB, Canada, July 24-27, 2005.
82. **K. Kaur**, S. Marcus, K. Kawulka, and J.C. Vederas*, Mechanism of Action of Class IIa Bacteriocin: Role of Key Amino Acid Residues in the Mannose-Specific Phosphotransferase System Receptor Protein, 88th Canadian Chemistry Conference and Exhibition, Saskatoon, SK, Canada, May 28 - June 1, 2005.
83. **L.A. Martin-Visscher**, L.J. Gursky, K. Kaur, S. Garneau, J.C. Vederas*, Toward the Structural Elucidation of an N-Terminally Blocked Bacteriocin, 88th Canadian Chemistry Conference and Exhibition, Saskatoon, SK, Canada, May 28 - June 1, 2005.
84. **L.J. Gursky**, M.J. van Belkum, M.E. Stiles, L.M. McMullen, J.C. Vederas*, K. Kaur, Bacteriocin Expression in *Carnobacterium maltaromaticum* UAL26 can be Induced Using Synthetic Piscicolin 126 Induction Peptide, 88th Canadian Chemistry Conference and Exhibition, Saskatoon, SK, Canada, May 28 - June 1, 2005.
85. **K. Kaur**, L.C. Andrew, D.S. Wishart, and J.C. Vederas*, Dynamic Relationships Among Type IIa Bacteriocins from Lactic Acid Bacteria, Peptides, Chemistry & Biology of, Gordon Research Conference, Ventura, California, February 15-20, 2004.
86. **K. Kaur**, J.C. Vederas*, L.C. Andrew, D.S. Wishart, Structure-Activity Relationship Among Type IIa Bacteriocins from Lactic Acid Bacteria: Importance of the C-terminal Amphipathic α-Helical Domain, 1st Banff Symposium on Organic Chemistry, Alberta, Canada, November 7-9, 2003.
87. **K. Kaur**, J.C. Vederas*, L.C. Andrew, D.S. Wishart, Solution Structure of Natural and Synthetic Pediocin: Structure-activity Relationship Among Type IIa Bacteriocins, International Symposium of Bioorganic Chemistry 6, Toronto, Canada, August 11-14, 2002.
88. **K. Kaur**, M.J.K. Lan, R.F. Pratt*, Mechanism of Reaction of Class C β-Lactamase with Cyclic Acyl Phosph(on)ates: "Penicillin-like" Inhibitors, International Symposium of Bioorganic Chemistry 6, Toronto, Canada, August 11-14, 2002.
89. **K. Kaur**, M.J.K. Lan, R.F. Pratt*, Cyclic Acyl Phosph(on)ates: “Penicillin-like” Inhibitors of the Class C β-Lactamase of *Enterobacter cloacae* P99, 222nd ACS National Meeting and Exposition, Chicago, August 26-30, 2001.
90. **K. Kaur** and R.F. Pratt*, Mechanism of Reaction of A Class C β-Lactamase with Submicromolar Substrates/Inhibitors: Acyl Phosph(on)ates, 222nd ACS National Meeting and Exposition, Chicago, August 26-30, 2001.
91. **K. Kaur** and R.F. Pratt*, Acyl Phosph(on)ates: Submicromolar Substrates/Inhibitors of the Class C β-Lactamase of *Enterobacter cloacae* P99, 29th ACS Northeast Regional Meeting, University of Connecticut, Storrs, Connecticut, June 18-21, 2000.
92. **K. Kaur** and R.G. Salomon*, Effects of Taurine on Oxidative Modification of Low-Density Lipoprotein, 30th ACS Central Regional Meeting, Cleveland, Ohio, May 27-29, 1998.
93. **K. Kaur** and R.G. Salomon*, 2-(ω-Carboxyalkyl)Pyrroles: Immunodetection in Oxidized Low Density Lipoproteins and Human Plasma, 214th ACS National Meeting and Exposition, Las Vegas, Nevada, September 7-11, 1997.

94. **K. Kaur** and R.G. Salomon*, Carboxyalkyl Pyrroles: Synthesis and Immunodetection in Human Plasma, Meeting-in-Miniature American Chemical Society, Cleveland State University, Cleveland, Ohio, March 26, 1997.
95. **K. Kaur** and R.G. Salomon*, Non Protein-bound Products of LDL Oxidation, Levuglandin Symposium, Case Western Reserve University, Cleveland, Ohio, August 23, 1996.
96. **K. Kaur**, R.G. Salomon*, W. Sha, G. Xu, and L.M. Sayre, Formation of Lipid-Derived Pyrroles upon Oxidation of Low Density Lipoproteins, Regional American Chemical Society Meeting, Notre Dame College, Ohio, March 20, 1996.

III. TEACHING

A. TEACHING

Pharm. D. Courses (Chapman University)

PHRM 552 - Pharmacology/Med Chem, Integrated Therapeutics: Infectious Diseases I
PHRM 546 - Med Chem, Integrated Therapeutics: Gastroenterology
PHRM 537 - Med Chem, Integrated Therapeutics: Cardiology
PHRM 535 - Med Chem, Integrated Therapeutics: Dermatology & Rheumatology

Graduate Courses (Chapman University)

PHS 612 - Advanced Principles of Drug Action
PHS 702 - Research Methods

Undergraduate Courses (taught in the past at University of Alberta)

PHARM 301 - Principles of Drug Action and Disposition - Introduction to Medicinal Chemistry
PHARM 307 - Medicinal Chemistry, Dermatology Module
PHARM 357 - Medicinal Chemistry, Gastrointestinal Module
PHARM 437 - Medicinal Chemistry, Bone and Joint Module
PHARM 499 - Medicinal Chemistry, Women's and Men's Health Module
PHARM 498 - Research and Directed Studies
PHARM 341 - Pharmaceutical Analysis
PHARM 367 - Medicinal Chemistry, Cardiology Module
PHARM 417 - Medicinal Chemistry, Neurology Module
IntD 410 - Interdisciplinary Health Team Development

Graduate Courses (taught in the past at University of Alberta)

PHARM 570 - Advanced Pharmaceutical Analysis (UV/Vis, IR, Raman, and NMR Spectroscopy)
PHARM 573 - Analytical Techniques in Pharmaceutical Sciences (Extraction methods, Fluorescenc -e Spectroscopy and Isothermal Titration Calorimetry)
PHARM 610 - Advanced Drug Delivery Systems (Peptides and Proteins for Drug Targeting)

B. POSTDOC/STUDENT SUPERVISION

<u>Postdoctoral Fellows</u> [n=7]

Dr. Hanieh Ariani

Period: 03/2016- 09/2018
Project: Engineering peptide-drug conjugates for targeting breast cancer cells

Dr. Amaresh Sahoo
Period: 09/2015- 01/2016
Project: Peptide-based platforms for detection of bacteria

Dr. Rania Soudy (co-supervised)
Period: 01/2014- 05/2016
Project: Peptide antagonists for Amylin receptor

Dr. Ramana Dangeti (co-supervised)
Period: 06/2013- 04/2016
Project: Bacteriocins as alternatives to conventional antibiotics

Dr. Sarfuddin Azmi
Period: 03/2013- 01/2015
Project: Engineering antimicrobial peptides for detecting pathogenic Gram-positive bacteria

Dr. Sahar Ahmed
Period: 09/2011- 08/2012
Project: Development of peptide-based diagnostic assay for quantification of polyaromatic acids

Dr. Anu Mathews (co-supervised)
Period: 09/2009- 08/2010
Project: Peptide-micelle engineering for the design of novel specific cancer targeting agents

Graduate Students [n=24]

Current

Ph.D. Jane (Shih-Jing) Yao (Fall 2021-present)

MSPS Riad Bellili (Spring 2024-present)

Completed

Ph.D. Azam Saghaeidehkordi, 2021
Ph.D. Elmira Ziaei, 2021
Ph.D. Hashem Etayash, 2017 (co-supervised, main supervisor: K. Kaur)
Ph.D. Hamed Kohan, 2013 (co-supervised, main supervisor: F. Jamali)
Ph.D. Rania Soudy, 2012
Ph.D. Dharmendra Raghuwanshi, 2012
Ph.D. Wael Soliman, 2011
Ph.D. Sahar Ahmed, 2010

MSPS Phi-Phung Than, Aug 2022
MSPS Cassandra Dill, Aug 2020 (main supervisor: K. Kaur; co-supervisor: S. Yang)
MSPS Emad Althagafi, Aug 2018
MSPS Azam Saghaeidehkordi, Aug 2018
MSPS Yazeed Alanazi, Apr 2018
MSPS Elmira Ziaei, Dec 2017
MSPS Kim Tushar, Aug 2017

M.Sc. Yogita Raghuwanshi, 2015
M.Sc. Harpreet Dhingra, 2013 (co-supervised by K. Kaur and B. Singh)
M.Sc. Hashem Etayash, 2012
M.Sc. Minashree Singh, 2012 (main supervisor: S. Mitra; co-supervisor: K. Kaur)
M.Sc. Krishna Bodapati, 2011
M.Sc. Gagandeep Kharaud, 2010
M.Sc. Reem Beleid, 2008

Other Students (Pharm.D. or Undergraduate Research Students) [n=29]

18 Students
Chapman University, School of Pharmacy (2016-present)
Enrolled as Capstone, Pharm.D. research or Student faculty independent research

11 Students
University of Alberta, Faculty of Pharmacy and Pharmaceutical Sciences (2004-2014)
Enrolled as Summer Research Students

1V. SERVICE

A. STUDENT COMMITTEES

Examining Committee Member

2004-present 55 exams (M.Sc. thesis defense or Ph.D. candidacy exam or Ph.D. thesis defense)

Supervisory Committee Member

2015-present Supervisory committee member for 10 graduate (MSPS or Ph.D.) students at CUSP

2004-2015 Supervisory committee member for 11 students (M.Sc. or Ph.D.) at Univ. of Alberta

B. COMMITTEES

School of Pharmacy (CUSP)

2022-2024	Chair, Graduate Program Committee (GPC)
2016-2020	Chair, Faculty Review Committee (FRC)
2016-2018	Chair, Science Committee
2016-2017	Chair, Faculty Search Sub-Committee-Natural Products, BPS
2015-2016	Chair, Faculty Search Sub-Committee-Immunology, BPS
2021-present	Member, Science Committee
2019-present	Member, Graduate Program Committee (GPC)
2015-present	Member, Faculty Review Committee (FRC)
2021-2022	Dean's Council BPS Representative
2017-2021	Member, Student Affairs Committee
2017-2019	Member, Strategic Planning Committee

2017-2018	Member, Item Review Committee
2016-2019	Member, Science Committee
2014-2017	Member, Assessment Committee

Chapman University

2022-2024	Member, Faculty Development Council
2019-2022	Member, University Assessment Committee
2018-2021	Member, Faculty Grievance Board

Outside University (External)

2023-2025	Long Range Planning Committee (LRPC) Member, Medicinal Chemistry Division, American Chemical Society (ACS)
2019-2022	Member, Website Committee, American Peptide Society (APS)

C. OTHER

2024	Curriculum Review Working Group, CUSP
2018-present	Peer Teaching Evaluator, CUSP
2017-2022	Mentor for Junior Faculty, CUSP
2014-present	Active participation in ACPE accreditation, CUSP

D. VOLUNTEER AND PUBLIC SERVICE

1. Judge for the "Poster Presentation Competition" at the 27th American Peptide Symposium, Whistler, BC, Canada, June 11-16, 2022.
2. Judge for the "Irvine Unified School District's 38th Annual Science Fair" at the Northwood High School, Irvine, CA, USA, Feb 06, 2019.
3. Invited Presentation at the "21st Century Career Conference" organized by Irvine Unified School District (IUSD), The Beckman Center, Irvine, CA, USA, Dec 13, 2018.
4. Organized the first "Chapman University School of Pharmacy Research Day" as the chair of the CUSP Science Committee, May 04, 2018.
5. Volunteer at the Irvine Unified School District - Ask-A-Scientist/Engineer Night, Rancho San Joaquin Middle School, Irvine, CA, Aug 31, 2017.
6. Judge for the "Poster Presentation Competition" at the 25th American Peptide Symposium, Whistler, BC, Canada, June 17-22, 2017.
7. Judge for the "Poster Presentation Competition" at the 2016 Irvine Unified School District Science Fair, Irvine High School, Irvine, USA, Feb 23, 2016.
8. Wrote an article for Orange County Register "In Living Textbooks", June 2015.
9. Judge for the "PDF Poster Presentation Competition" at the 3rd Western Canadian Medicinal Chemistry Workshop, Saskatoon, SK, Canada, September 28-30, 2012.

10. Organizer and Panel member at the Science and Technology Partnership (ISTP) Indo-Canadian Workshop "Joint Indo-Canadian Meeting on Development of Low-Cost Lab-on-a-chip Medical Devises for Health Monitoring" January 7-11, 2011, IIT Bombay, India.
11. Judge for the "Graduate Student Oral Presentation Competition" at the 94th Canadian Chemistry Conference and Exhibition, Montreal, Quebec, Canada, June 5- 9, 2011.
12. Judge for the student presentations (oral and poster) at the "Annual Faculty Research and Development Day" 2005-present.
13. Medicinal Chemistry Laboratory Orientation: High School Students, Women in Scholarship, Engineering, Science and Technology (WISEST) Program (2010)
14. Reviewer for British Columbia Innovation Scholars (2010)
15. Reviewer for GSK/AFPC Student Paper Awards (2010, 2011)
16. External Ph.D. Proposal Reviewer, School of Medicine, University of Alberta (2008)
17. Supported Heritage Youth Researcher Summer (HYRS) Program by training a high school student (2005)